Company Description
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibo...
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Valuation
Price to Book Ratio
0.46
Enterprise Value to EBITDA
0.87
Efficiency
Liquidity
Current Ratio
15.06
Quick Ratio
15.06
Cash Ratio
14.86
Profitability
Return on Assets
-48.11
Return on Equity
-52.81
Return on Total Capital
-53.10
Capital Structure
Total Debt to Total Assets
0.97
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. David Hering | 46 | 2021 | Chief Operating Officer |
Mr. Jeremy Gowler | - | 2022 | Chief Operating Officer |
Mr. Frederick W. Driscoll | 70 | 2022 | Chief Financial & Accounting Officer |
Ms. Stacy Price | - | 2023 | Chief Technology & Manufacturing Officer |
Dr. Robert D. Allen | - | 2023 | Chief Scientific Officer |
Insider Actions
09/01/2022 |
David Hering Chief Executive Officer; Director |
8,000 | Acquisition at $4.52 per share. | 36,160 |
08/19/2022 |
M28 Capital Management LP Director |
584,451 | Acquisition at $4.62 per share. | 2,700,163 |
08/18/2022 |
M28 Capital Management LP Director |
1,265,549 | Acquisition at $4.31 per share. | 5,454,516 |
08/17/2022 |
M28 Capital Management LP Director |
1,000,000 | Acquisition at $4.04 per share. | 4,040,000 |
03/03/2022 |
Adimab LLC |
1,158,089 | 0 | |
08/10/2021 |
Adimab LLC |
25,860,700 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Mithril Capital Management LLC |
9,244,580 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
320,160 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
4,755,460 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
28,520 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
19,540 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
55,595 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Polaris Growth Management LLC |
2,852,425 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Redmile Group LLC |
1,920,960 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2021 |
Mithril Capital Management LLC |
1,997,000 | Acquisition at $17 per share. | 33,949,000 |
08/10/2021 |
Polaris Growth Management LLC |
177,500 | Acquisition at $17 per share. | 3,017,500 |
08/10/2021 |
Polaris Growth Management LLC |
45,000 | Acquisition at $17 per share. | 765,000 |
08/10/2021 |
Polaris Growth Management LLC |
2,678 | Acquisition at $17 per share. | 45,526 |
08/10/2021 |
Polaris Growth Management LLC |
1,834 | Acquisition at $17 per share. | 31,178 |
08/10/2021 |
Polaris Growth Management LLC |
5,219 | Acquisition at $17 per share. | 88,723 |
08/10/2021 |
Polaris Growth Management LLC |
267,769 | Acquisition at $17 per share. | 4,552,073 |
08/10/2021 |
Redmile Group LLC |
1,470,000 | Acquisition at $17 per share. | 24,990,000 |
MarketWatch News on ADGI
-
Biotech Stocks Are Still Falling. The Near-Term Outlook Is Grim.
- Barron's Online
-
Adagio Stock Spikes on New Data, but Its Omicron Problems Remain
- Barron's Online
-
Adagio Therapeutics downgraded to underweight at Morgan Stanley
- Tomi Kilgore
-
Adagio Therapeutics downgraded to hold from buy at Stifel, price target slashed to $9 from $50
- Tonya Garcia
-
Regeneron Says Covid-19 Treatment Might Not Work as Well Against Omicron
- Barron's Online
-
Adagio Therapeutics upgraded to overweight at Morgan Stanley
- Tomi Kilgore
-
Adagio Therapeutics started at buy with $57 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
The IPO Market Is on Break. Adagio Is Friday's Only Deal.
- Barron's Online
-
Adagio Therapeutics sets IPO terms, to be valued at up to $1.8 bln
- Tomi Kilgore
Other News on ADGI
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
Invivyd Names Fred Driscoll as Interim CFO, Cuts Some Positions
- The Wall Street Journal Interactive Edition
-
10-Q: ADAGIO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Why Adagio Therapeutics Stock Is Soaring Today
- Motley Fool